台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

(ME1-1) Challenging situations in robot-assisted partial nephrectomy_呂育全

2022-09-28 • 觀看: 14 • 回應: 0 • 影片
(IS5-1) Complications of PCNL : Risk factors and management PCNL的風險防控_石宏仁

2022-09-28 • 觀看: 28 • 回應: 0 • 影片
(IS4-2) Pathophysiology of IC/BPS and potential urinary biomarkers for diagnosis_阮雍順

2022-09-28 • 觀看: 19 • 回應: 0 • 影片
(IS4-1) Current classification and differential diagnosis of interstitial cystitis/ bladder pain syndrome – based on clinical symptoms, urodynamic tests, and histological study_蒙恩

2022-09-28 • 觀看: 27 • 回應: 0 • 影片
(IS4-3) Novel treatments of different subtypes of interstitial cystitis/ bladder pain syndrome – medical, intravesical treatment, surgery_張嘉峰

2022-09-28 • 觀看: 13 • 回應: 0 • 影片
(IS3-2) Risk of metabolic and cardiovascular adverse events with NHA among men with advanced prostate cancer_陳毓騏

2022-09-28 • 觀看: 19 • 回應: 0 • 影片
(IS3-1) Real-world evidence of using NHA in Taiwanese prostate cancer patients_陳忠信

2022-09-28 • 觀看: 27 • 回應: 0 • 影片
(LS4-1) Myths about bone-targeted therapy: Optimal strategy for incorporating BTAs into treatment paradigms for PCa_洪健華

2022-09-28 • 觀看: 27 • 回應: 0 • 影片
(IS2-1) Under the spotlight: Recent updates on FGFR in urothelial carcinoma_陳忠信

2022-09-28 • 觀看: 32 • 回應: 0 • 影片
(IS1-1) How to implement precision therapies for prostate cancer in clinical practice？ _蘇柏榮

2022-09-28 • 觀看: 32 • 回應: 0 • 影片
(TSD-1) The impact of prostate health index (PHI) in prostate cancer diagnosis：Difference in Asians and Caucasians _蔣智宏

2022-09-28 • 觀看: 49 • 回應: 0 • 影片
(TSD-2) The advancing role of PSMA radioligand therapy in metastatic prostate cancer_Fred Saad

2022-09-28 • 觀看: 39 • 回應: 0 • 影片

Prev
318
319
320
321
322
323
324
325
326
327
Next
/ 1056